Taking cholesterol drugs called evolocumab or alirocumab doesn’t seem to raise your risk of bleeding in the brain — the numbers show it’s about the same as not taking them.
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
Taking cholesterol drugs called evolocumab or alirocumab doesn’t seem to raise your risk of bleeding in the brain — the numbers show it’s about the same as not taking them.
See the technical phrasing
Treatment with the PCSK9 inhibitors evolocumab or alirocumab is not associated with a statistically significant difference in the risk of hemorrhagic stroke compared to control groups, with a relative risk of 1.041 (95% confidence interval: 0.690–1.573), indicating no detectable increase in bleeding-related brain events.
What the research says
Supports
1 study
Study: Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials.
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies